Lifeloc Technologies Reports Q3 2025 Revenue Up 8% but Net Loss Widens to $263K

Lifeloc Technologies, Inc

2025-Q3 EPS reported -$0.35 revenue$6,753,858

Q3 2025 net revenue $2.257M, up 8% from $2.087M in Q3 2024, but net loss increased to $(263K) from $(158K).
Gross margin declined to 40.2% from 43.7% due to cost inflation and tariffs.
SpinDetect centrifugal drug analyzer beta testing for THC detection underway; commercial launch expected in 2026.
Nine-month 2025 net loss $(950K) vs $(740K) same period 2024, revenue $6.754M vs $6.628M.
Shares began trading on OTCID July 1, 2025, replacing OTC Pink.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.